LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Thera… Read more
LENZ Therapeutics Inc (LENZ) - Net Assets
Latest net assets as of September 2025: $193.93 Million USD
Based on the latest financial reports, LENZ Therapeutics Inc (LENZ) has net assets worth $193.93 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($210.70 Million) and total liabilities ($16.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $193.93 Million |
| % of Total Assets | 92.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
LENZ Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how LENZ Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LENZ Therapeutics Inc (2019–2024)
The table below shows the annual net assets of LENZ Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $204.08 Million | +320.13% |
| 2023-12-31 | $-92.71 Million | -283.60% |
| 2022-12-31 | $-24.17 Million | -70.04% |
| 2021-12-31 | $-14.21 Million | -45.04% |
| 2020-12-31 | $-9.80 Million | -341.84% |
| 2019-12-31 | $-2.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LENZ Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14279600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $196.00K | 0.10% |
| Other Components | $348.90 Million | 170.96% |
| Total Equity | $204.08 Million | 100.00% |
LENZ Therapeutics Inc Competitors by Market Cap
The table below lists competitors of LENZ Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lumax International Corp Ltd
TW:6192
|
$250.66 Million |
|
Shijiazhuang Kelin Elec Co
SHG:603050
|
$250.69 Million |
|
Jamna Auto Industries Limited
NSE:JAMNAAUTO
|
$250.73 Million |
|
SK Discovery Co Ltd
KO:006125
|
$250.89 Million |
|
Supermax Corporation Berhad
PINK:SPMXF
|
$250.64 Million |
|
XP Power Limited
PINK:XPPLF
|
$250.56 Million |
|
PONCE FIN. GROUP DL -01
F:73V0
|
$250.54 Million |
|
Piraeus Port Authority S.A
AT:PPA
|
$250.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LENZ Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -92,712,000 to 204,084,000, a change of 296,796,000.
- Net loss of 49,769,000 reduced equity.
- New share issuances of 79,513,000 increased equity.
- Other comprehensive income increased equity by 190,000.
- Other factors increased equity by 266,862,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-49.77 Million | -24.39% |
| Share Issuances | $79.51 Million | +38.96% |
| Other Comprehensive Income | $190.00K | +0.09% |
| Other Changes | $266.86 Million | +130.76% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares LENZ Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.27 | $12.50 | x |
| 2020-12-31 | $-1.18 | $12.50 | x |
| 2021-12-31 | $-1.72 | $12.50 | x |
| 2022-12-31 | $-3.08 | $12.50 | x |
| 2023-12-31 | $-11.38 | $12.50 | x |
| 2024-12-31 | $9.59 | $12.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LENZ Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-24.39%) is below the historical average (-4.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $112.80K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-67.39 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-69.34 Million |
| 2022 | 0.00% | -72.07% | 0.32x | 0.00x | $-8.39 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-60.70 Million |
| 2024 | -24.39% | 0.00% | 0.00x | 1.05x | $-70.18 Million |
Industry Comparison
This section compares LENZ Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LENZ Therapeutics Inc (LENZ) | $193.93 Million | 0.00% | 0.09x | $250.65 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |